VAS
ADAP

Vestmark Advisory Solutions’s Adaptimmune Therapeutics ADAP Stock Holding History

Vestmark Advisory Solutions’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-31,536
Closed -$252K – 589
2020
Q3 		$252K Buy
+31,536
New +$276K 0.03% 474

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vestmark Advisory Solutions's ADAP Position: Q4 2020 in Review

Vestmark Advisory Solutions sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 31,536 shares — an estimated $252K sold.

Vestmark Advisory Solutions first reported a position in ADAP in Q3 2020 and held it in 1 quarter. The position peaked at $252K in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Vestmark Advisory Solutions reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Vestmark Advisory Solutions sold 31,536 Adaptimmune Therapeutics shares in Q4 2020, an estimated $252K.
  • Vestmark Advisory Solutions first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Vestmark Advisory Solutions's Adaptimmune Therapeutics position peaked at $252K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Vestmark Advisory Solutions's 13F filing for Q4 2020, filed 4 Feb 2021.